{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:51:23Z","timestamp":1772164283241,"version":"3.50.1"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transcription factors play a central role in malignant transformation by activating or repressing waves of downstream target genes. Therapeutic targeting of transcription factors can reprogram cancer cells to lose their advantages in growth and survival. The BCL6 transcriptional repressor plays a central role in the pathogenesis of diffuse large B-cell lymphomas (DLBCL) and controls downstream checkpoints, including the p53 tumor suppressor gene. We report that a specific inhibitor of BCL6 called BPI can trigger a p53 response in DLBCL cells. This was partially due to induction of p53 activity and partially due to relief of direct repression by BCL6 of p53 target genes. BPI could thus induce a p53-like response even in the presence of mutant p53. Moreover, sequential BCL6 peptide inhibitors followed by p53 peptide or small-molecule activators provided a more powerful antilymphoma effect than either treatment alone by maximally restoring p53 target gene expression. Therefore, tandem targeting of the overlapping BCL6 and p53 transcriptional programs can correct aberrant survival pathways in DLBCL and might provide an effective therapeutic approach to lymphoma therapy. [Cancer Res 2008;68(9):3361\u20139]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5817","type":"journal-article","created":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T21:11:48Z","timestamp":1209676308000},"page":"3361-3369","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas"],"prefix":"10.1158","volume":"68","author":[{"given":"Leandro C.","family":"Cerchietti","sequence":"first","affiliation":[{"name":"1Developmental and Molecular Biology and Departments of"}]},{"given":"Jose M.","family":"Polo","sequence":"additional","affiliation":[{"name":"1Developmental and Molecular Biology and Departments of"}]},{"given":"Gustavo F.","family":"Da Silva","sequence":"additional","affiliation":[{"name":"1Developmental and Molecular Biology and Departments of"}]},{"given":"Pedro","family":"Farinha","sequence":"additional","affiliation":[{"name":"3Department of Pathology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and"}]},{"given":"Rita","family":"Shaknovich","sequence":"additional","affiliation":[{"name":"2Pathology, Albert Einstein College of Medicine, Bronx, New York;"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"3Department of Pathology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and"}]},{"given":"Steven F.","family":"Dowdy","sequence":"additional","affiliation":[{"name":"4Howard Hughes Medical Institute and Department of Cellular and Molecular Medicine, University of California at San Diego School of Medicine, La Jolla, California"}]},{"given":"Ari","family":"Melnick","sequence":"additional","affiliation":[{"name":"1Developmental and Molecular Biology and Departments of"}]}],"member":"1086","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"2022061700421842100_B1","doi-asserted-by":"crossref","unstructured":"Pasqualucci L, Bereschenko O, Niu H, et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk Lymphoma\u20082003; 44 Suppl 3: S5\u201312.","DOI":"10.1080\/10428190310001621588"},{"key":"2022061700421842100_B2","doi-asserted-by":"crossref","unstructured":"Cattoretti G, Pasqualucci L, Ballon G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell\u20082005; 7: 445\u201355.","DOI":"10.1016\/j.ccr.2005.03.037"},{"key":"2022061700421842100_B3","doi-asserted-by":"crossref","unstructured":"Baron BW, Anastasi J, Montag A, et al. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A\u20082004; 101: 14198\u2013203.","DOI":"10.1073\/pnas.0406138101"},{"key":"2022061700421842100_B4","doi-asserted-by":"crossref","unstructured":"Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature\u20082004; 432: 635\u20139.","DOI":"10.1038\/nature03147"},{"key":"2022061700421842100_B5","doi-asserted-by":"crossref","unstructured":"Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol\u20082005; 6: 1054\u201360.","DOI":"10.1038\/ni1245"},{"key":"2022061700421842100_B6","doi-asserted-by":"crossref","unstructured":"Polo JM, Juszczynski P, Monti S, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A\u20082007; 104: 3207\u201312.","DOI":"10.1073\/pnas.0611399104"},{"key":"2022061700421842100_B7","doi-asserted-by":"crossref","unstructured":"Ranuncolo SM, Polo JM, Dierov J, et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol\u20082007; 8: 705\u201314.","DOI":"10.1038\/ni1478"},{"key":"2022061700421842100_B8","doi-asserted-by":"crossref","unstructured":"Polo JM, Dell'Oso T, Ranuncolo SM, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med\u20082004; 10: 1329\u201335.","DOI":"10.1038\/nm1134"},{"key":"2022061700421842100_B9","doi-asserted-by":"crossref","unstructured":"Huynh KD, Bardwell VJ. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene\u20081998; 17: 2473\u201384.","DOI":"10.1038\/sj.onc.1202197"},{"key":"2022061700421842100_B10","doi-asserted-by":"crossref","unstructured":"Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev\u20082000; 14: 1810\u201323.","DOI":"10.1101\/gad.14.14.1810"},{"key":"2022061700421842100_B11","doi-asserted-by":"crossref","unstructured":"Ahmad KF, Melnick A, Lax S, et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell\u20082003; 12: 1551\u201364.","DOI":"10.1016\/S1097-2765(03)00454-4"},{"key":"2022061700421842100_B12","doi-asserted-by":"crossref","unstructured":"Parekh S, Polo JM, Shaknovich R, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood\u20082007; 110: 2067\u201374.","DOI":"10.1182\/blood-2007-01-069575"},{"key":"2022061700421842100_B13","doi-asserted-by":"crossref","unstructured":"Melnick A. Predicting the effect of transcription therapy in hematologic malignancies. Leukemia\u20082005; 19: 1109\u201317.","DOI":"10.1038\/sj.leu.2403777"},{"key":"2022061700421842100_B14","doi-asserted-by":"crossref","unstructured":"Prive GG, Melnick A. Specific peptides for the therapeutic targeting of oncogenes. Curr Opin Genet Dev\u20082006; 16: 71\u20137.","DOI":"10.1016\/j.gde.2005.12.010"},{"key":"2022061700421842100_B15","doi-asserted-by":"crossref","unstructured":"Melnick A, Licht JD. Deconstructing a disease: RAR\u03b1, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood\u20081999; 93: 3167\u2013215.","DOI":"10.1182\/blood.V93.10.3167.410k44_3167_3215"},{"key":"2022061700421842100_B16","doi-asserted-by":"crossref","unstructured":"Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell\u20082002; 1: 289\u201398.","DOI":"10.1016\/S1535-6108(02)00047-8"},{"key":"2022061700421842100_B17","doi-asserted-by":"crossref","unstructured":"Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene\u20082007; 26: 2243\u201354.","DOI":"10.1038\/sj.onc.1210295"},{"key":"2022061700421842100_B18","doi-asserted-by":"crossref","unstructured":"Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol\u20082004; 2: E36.","DOI":"10.1371\/journal.pbio.0020036"},{"key":"2022061700421842100_B19","doi-asserted-by":"crossref","unstructured":"Renvoize C, Biola A, Pallardy M, Breard J. Apoptosis: identification of dying cells. Cell Biol Toxicol\u20081998; 14: 111\u201320.","DOI":"10.1023\/A:1007429904664"},{"key":"2022061700421842100_B20","doi-asserted-by":"crossref","unstructured":"Cohen JJ. Apoptosis. Immunol Today\u20081993; 14: 126\u201330.","DOI":"10.1016\/0167-5699(93)90214-6"},{"key":"2022061700421842100_B21","doi-asserted-by":"crossref","unstructured":"Farrugia MM, Duan LJ, Reis MD, Ngan BY, Berinstein NL. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. Blood\u20081994; 83: 191\u20138.","DOI":"10.1182\/blood.V83.1.191.bloodjournal831191"},{"key":"2022061700421842100_B22","doi-asserted-by":"crossref","unstructured":"Mehra S, Messner H, Minden M, Chaganti RS. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Genes Chromosomes Cancer\u20082002; 33: 225\u201334.","DOI":"10.1002\/gcc.10025"},{"key":"2022061700421842100_B23","doi-asserted-by":"crossref","unstructured":"Chang H, Blondal JA, Benchimol S, Minden MD, Messner HA. p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leuk Lymphoma\u20081995; 19: 165\u201371.","DOI":"10.3109\/10428199509059672"},{"key":"2022061700421842100_B24","doi-asserted-by":"crossref","unstructured":"Taylor WR, Stark GR. Regulation of the G2\/M transition by p53. Oncogene\u20082001; 20: 1803\u201315.","DOI":"10.1038\/sj.onc.1204252"},{"key":"2022061700421842100_B25","doi-asserted-by":"crossref","unstructured":"Gudkov AV, Komarova EA. Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun\u20082005; 331: 726\u201336.","DOI":"10.1016\/j.bbrc.2005.03.153"},{"key":"2022061700421842100_B26","doi-asserted-by":"crossref","unstructured":"Wang W, El-Deiry WS. Targeting p53 by PTD-mediated transduction. Trends Biotechnol\u20082004; 22: 431\u20134.","DOI":"10.1016\/j.tibtech.2004.07.002"},{"key":"2022061700421842100_B27","doi-asserted-by":"crossref","unstructured":"Dinnen RD, Drew L, Petrylak DP, et al. Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance. J Biol Chem\u20082007; 282: 26675\u201386.","DOI":"10.1074\/jbc.M701864200"},{"key":"2022061700421842100_B28","doi-asserted-by":"crossref","unstructured":"Fingrut O, Reischer D, Rotem R, et al. Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells. Br J Pharmacol\u20082005; 146: 800\u20138.","DOI":"10.1038\/sj.bjp.0706394"},{"key":"2022061700421842100_B29","doi-asserted-by":"crossref","unstructured":"Kroemer G, El-Deiry WS, Golstein P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ\u20082005; 12 Suppl 2: 1463\u20137.","DOI":"10.1038\/sj.cdd.4401724"},{"key":"2022061700421842100_B30","unstructured":"Eguchi Y, Shimizu S, Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res\u20081997; 57: 1835\u201340."},{"key":"2022061700421842100_B31","doi-asserted-by":"crossref","unstructured":"Ha HC, Snyder SH. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A\u20081999; 96: 13978\u201382.","DOI":"10.1073\/pnas.96.24.13978"},{"key":"2022061700421842100_B32","doi-asserted-by":"crossref","unstructured":"Ying W, Alano CC, Garnier P, Swanson RA. NAD+ as a metabolic link between DNA damage and cell death. J Neurosci Res\u20082005; 79: 216\u201323.","DOI":"10.1002\/jnr.20289"},{"key":"2022061700421842100_B33","doi-asserted-by":"crossref","unstructured":"Los M, Mozoluk M, Ferrari D, et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell\u20082002; 13: 978\u201388.","DOI":"10.1091\/mbc.01-05-0272"},{"key":"2022061700421842100_B34","doi-asserted-by":"crossref","unstructured":"Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med\u20082002; 8: 282\u20138.","DOI":"10.1038\/nm0302-282"},{"key":"2022061700421842100_B35","doi-asserted-by":"crossref","unstructured":"Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res\u20082005; 7: R765\u201374.","DOI":"10.1186\/bcr1290"},{"key":"2022061700421842100_B36","doi-asserted-by":"crossref","unstructured":"Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood\u20082003; 101: 1220\u201335.","DOI":"10.1182\/blood-2002-07-2009"},{"key":"2022061700421842100_B37","doi-asserted-by":"crossref","unstructured":"Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia\u20082007; 21: 2332\u201343.","DOI":"10.1038\/sj.leu.2404856"},{"key":"2022061700421842100_B38","doi-asserted-by":"crossref","unstructured":"Cerchietti L, Figueroa M, Meyers D, Cole P, Bhalla K, Melnick A. Connectivity mapping of BCL6 targeted therapy guides rational design of potent and specific non-chemotherapy combinatorial regimens in DLBCL. Blood\u20082007; 110: 161a.","DOI":"10.1182\/blood.V110.11.523.523"},{"key":"2022061700421842100_B39","doi-asserted-by":"crossref","unstructured":"Fujita N, Jaye DL, Geigerman C, et al. MTA3 and the Mi-2\/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell\u20082004; 119: 75\u201386.","DOI":"10.1016\/j.cell.2004.09.014"},{"key":"2022061700421842100_B40","doi-asserted-by":"crossref","unstructured":"Wang W, Rastinejad F, El-Deiry WS. Restoring p53-dependent tumor suppression. Cancer Biol Ther\u20082003; 2: S55\u201363.","DOI":"10.4161\/cbt.203"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/9\/3361\/2602285\/3361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/9\/3361\/2602285\/3361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:36:36Z","timestamp":1655433396000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/9\/3361\/543166\/Sequential-Transcription-Factor-Targeting-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,1]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2008,5,1]]},"published-print":{"date-parts":[[2008,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5817","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6498282.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376628","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6498282","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376628.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,1]]}}}